These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

393 related articles for article (PubMed ID: 35850429)

  • 1. Patterns of Use, Outcomes, and Resource Utilization among Recipients of Commercial Axicabtagene Ciloleucel and Tisagenlecleucel for Relapsed/Refractory Aggressive B Cell Lymphomas.
    Riedell PA; Hwang WT; Nastoupil LJ; Pennisi M; McGuirk JP; Maziarz RT; Bachanova V; Oluwole OO; Brower J; Flores OA; Ahmed N; Schachter L; Bharucha K; Dholaria BR; Schuster SJ; Perales MA; Bishop MR; Porter DL
    Transplant Cell Ther; 2022 Oct; 28(10):669-676. PubMed ID: 35850429
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Axicabtagene Ciloleucel versus Tisagenlecleucel for Relapsed or Refractory Large B Cell Lymphoma: A Systematic Review and Meta-Analysis.
    Gagelmann N; Bishop M; Ayuk F; Bethge W; Glass B; Sureda A; Pasquini MC; Kröger N
    Transplant Cell Ther; 2024 Jun; 30(6):584.e1-584.e13. PubMed ID: 38281590
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-World Outcomes with Chimeric Antigen Receptor T Cell Therapies in Large B Cell Lymphoma: A Systematic Review and Meta-Analysis.
    Jacobson CA; Munoz J; Sun F; Kanters S; Limbrick-Oldfield EH; Spooner C; Mignone K; Ayuk F; Sanderson R; Whitmore J; Wang Y; Xu H; Dickinson M
    Transplant Cell Ther; 2024 Jan; 30(1):77.e1-77.e15. PubMed ID: 37890589
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Cost-Effectiveness Analysis of Axicabtagene Ciloleucel versus Tisagenlecleucel in the Treatment of Diffuse Large B-cell Lymphoma Based on a Real-World French Registry.
    Ray M; Castaigne JG; Zang A; Patel A; Hancock E; Brighton N; Bachy E
    Adv Ther; 2024 Nov; 41(11):4282-4298. PubMed ID: 39316290
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma.
    Bachy E; Le Gouill S; Di Blasi R; Sesques P; Manson G; Cartron G; Beauvais D; Roulin L; Gros FX; Rubio MT; Bories P; Bay JO; Llorente CC; Choquet S; Casasnovas RO; Mohty M; Guidez S; Joris M; Loschi M; Carras S; Abraham J; Chauchet A; Drieu La Rochelle L; Deau-Fischer B; Hermine O; Gastinne T; Tudesq JJ; Gat E; Broussais F; Thieblemont C; Houot R; Morschhauser F
    Nat Med; 2022 Oct; 28(10):2145-2154. PubMed ID: 36138152
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Single center, real-world retrospective study of CAR-T cell therapy for relapsed/refractory large B-cell lymphoma beyond second line: five-year results at the University Hospitals Leuven.
    Brijs J; Van Ham J; Dubois B; Sinap F; Vergote V; Dierickx D; Vandenberghe P
    Acta Clin Belg; 2024 Aug; 79(4):276-284. PubMed ID: 39415456
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-Effectiveness of Chimeric Antigen Receptor T Cell Therapy in Patients with Relapsed or Refractory Large B Cell Lymphoma: No Impact of Site of Care.
    Cummings Joyner AK; Snider JT; Wade SW; Wang ST; Buessing MG; Johnson S; Gergis U
    Adv Ther; 2022 Aug; 39(8):3560-3577. PubMed ID: 35689726
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcomes of CD19-Directed Chimeric Antigen Receptor T Cell Therapy for Transformed Nonfollicular Lymphoma.
    Dong N; Rubio Lopes-Garcia L; Viñal D; Bachmeier C; Shah BD; Nishihori T; Khimani F; Davila ML; Lazaryan A; Pinilla-Ibarz J; Locke FL; Jain MD; Chavez JC
    Transplant Cell Ther; 2023 Jun; 29(6):349.e1-349.e8. PubMed ID: 36878427
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Axicabtagene ciloleucel compared to tisagenlecleucel for the treatment of aggressive B-cell lymphoma.
    Kwon M; Iacoboni G; Reguera JL; Corral LL; Morales RH; Ortiz-Maldonado V; Guerreiro M; Caballero AC; Domínguez MLG; Pina JMS; Mussetti A; Sancho JM; Bastos-Oreiro M; Catala E; Delgado J; Henriquez HL; Sanz J; Calbacho M; Bailén R; Carpio C; Ribera JM; Sureda A; Briones J; Hernandez-Boluda JC; Cebrián NM; Martin JLD; Martín A; Barba P
    Haematologica; 2023 Jan; 108(1):110-121. PubMed ID: 35770532
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Commercial anti-CD19 CAR T cell therapy for patients with relapsed/refractory aggressive B cell lymphoma in a European center.
    Sesques P; Ferrant E; Safar V; Wallet F; Tordo J; Dhomps A; Karlin L; Brisou G; Vercasson M; Hospital-Gustem C; Schwiertz V; Ranchon F; Rioufol C; Choquet M; Sujobert P; Ghergus D; Bouafia F; Golfier C; Lequeu H; Lazareth A; Novelli S; Devic P; Traverse Glehen A; Viel S; Venet F; Mialou V; Hequet O; Chauchet A; Arkam Y; Nicolas-Virelizier E; Peyrade F; Cavalieri D; Ader F; Ghesquières H; Salles G; Bachy E
    Am J Hematol; 2020 Nov; 95(11):1324-1333. PubMed ID: 32744738
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of axicabtagene ciloleucel versus tisagenlecleucel for the treatment of 3L + relapsed/refractory large B-cell lymphoma in the United States: incorporating longer survival results.
    Oluwole OO; Ray MD; Davies N; Bradford R; Jones C; Patel AR; Locke FL
    J Med Econ; 2024; 27(1):230-239. PubMed ID: 38240256
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Single center, real-world retrospective study of CAR-T cell therapy for relapsed/refractory large B-cell lymphoma beyond second line: five-year results at the University Hospitals Leuven.
    Brijs J; Van Ham J; Dubois B; Sinap F; Vergote V; Dierickx D; Vandenberghe P
    Acta Clin Belg; 2024 Sep; ():1-9. PubMed ID: 39291840
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparing Efficacy, Safety, and Preinfusion Period of Axicabtagene Ciloleucel versus Tisagenlecleucel in Relapsed/Refractory Large B Cell Lymphoma.
    Oluwole OO; Jansen JP; Lin VW; Chan K; Keeping S; Navale L; Locke FL
    Biol Blood Marrow Transplant; 2020 Sep; 26(9):1581-1588. PubMed ID: 32561336
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-world healthcare resource utilization and costs associated with tisagenlecleucel and axicabtagene ciloleucel among patients with diffuse large B-cell lymphoma: an analysis of hospital data in the United States.
    Maziarz RT; Yang H; Liu Q; Wang T; Zhao J; Lim S; Lee S; Dalal A; Bollu V
    Leuk Lymphoma; 2022 Sep; 63(9):2052-2062. PubMed ID: 35422192
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium.
    Nastoupil LJ; Jain MD; Feng L; Spiegel JY; Ghobadi A; Lin Y; Dahiya S; Lunning M; Lekakis L; Reagan P; Oluwole O; McGuirk J; Deol A; Sehgal AR; Goy A; Hill BT; Vu K; Andreadis C; Munoz J; Westin J; Chavez JC; Cashen A; Bennani NN; Rapoport AP; Vose JM; Miklos DB; Neelapu SS; Locke FL
    J Clin Oncol; 2020 Sep; 38(27):3119-3128. PubMed ID: 32401634
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Multicenter Real-life Prospective Study of Axicabtagene Ciloleucel versus Tisagenlecleucel Toxicity and Outcomes in Large B-cell Lymphomas.
    Stella F; Chiappella A; Casadei B; Bramanti S; Ljevar S; Chiusolo P; Di Rocco A; Tisi MC; Carrabba MG; Cutini I; Martino M; Dodero A; Bonifazi F; Santoro A; Sorà F; Botto B; Barbui AM; Russo D; Musso M; Grillo G; Krampera M; Olivieri J; Ladetto M; Cavallo F; Massaia M; Arcaini L; Pennisi M; Zinzani PL; Miceli R; Corradini P
    Blood Cancer Discov; 2024 Sep; 5(5):318-330. PubMed ID: 38953781
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimizing the post-CAR T monitoring period in recipients of axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucel.
    Ahmed N; Wesson W; Lutfi F; Porter DL; Bachanova V; Nastoupil LJ; Perales MA; Maziarz RT; Brower J; Shah GL; Chen AI; Oluwole OO; Schuster SJ; Bishop MR; McGuirk JP; Riedell PA
    Blood Adv; 2024 Oct; 8(20):5346-5354. PubMed ID: 39042880
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost effectiveness of axicabtagene ciloleucel versus tisagenlecleucel for adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy in the United States.
    Liu R; Oluwole OO; Diakite I; Botteman MF; Snider JT; Locke FL
    J Med Econ; 2021; 24(1):458-468. PubMed ID: 33691581
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dermatologic Adverse Events Associated With Chimeric Antigen Receptor T-Cell Therapy: A Pharmacovigilance Analysis of the FDA Reporting System.
    Storgard R; Dusza S; Shouval R; Scordo M; Markova A
    Transplant Cell Ther; 2024 Oct; 30(10):1035.e1-1035.e7. PubMed ID: 38945480
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Network meta-analysis of CAR T-Cell therapy for the treatment of 3L+ R/R LBCL after using published comparative studies.
    Oluwole OO; Neelapu SS; Ray MD; Limbrick-Oldfield EH; Wade SW; Kanters S; Patel AR; Locke FL
    Expert Rev Anticancer Ther; 2024 Jun; 24(6):457-465. PubMed ID: 38646700
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.